Nephros acquires GenArraytion for $1.2M in stock; gains PCR pathogen detection tech

NEPHROS INC

Purchase price of $1.2M paid via 123,981 shares of Nephros common stock.
50% of shares subject to forfeiture until intellectual property transition services completed.
Nephros to pay royalties on net sales of GenArraytion products over five years.
Registration statement covering issued shares must be filed within 60 days.
GenArraytion CEO Dr. Schaudies partners with Nephros VP Dr. Smith on product integration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.